NO20071825L - Transportprotein som blir brukt til a innfore kjemiske forbindelser i nerveceller - Google Patents

Transportprotein som blir brukt til a innfore kjemiske forbindelser i nerveceller

Info

Publication number
NO20071825L
NO20071825L NO20071825A NO20071825A NO20071825L NO 20071825 L NO20071825 L NO 20071825L NO 20071825 A NO20071825 A NO 20071825A NO 20071825 A NO20071825 A NO 20071825A NO 20071825 L NO20071825 L NO 20071825L
Authority
NO
Norway
Prior art keywords
transport protein
nerve cells
chemical compounds
protein used
introduce chemical
Prior art date
Application number
NO20071825A
Other languages
English (en)
Other versions
NO340732B1 (no
Inventor
Andreas Rummel
Original Assignee
Toxogen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxogen Gmbh filed Critical Toxogen Gmbh
Publication of NO20071825L publication Critical patent/NO20071825L/no
Publication of NO340732B1 publication Critical patent/NO340732B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Foreliggende oppfinnelse vedrører et transportprotein som kan oppnås ved modifisering av den tunge kjeden til det av Clostridium botulinum dannede nevrotoksin, hvilket protein spesifikt binder seg til nerveceller med høyere affinitet enn det native nevrotoksin. Videre vedrører oppfinnelsen en fremgangsmåte for fremstilling av transportproteinet, nukleinsyrer som koder transportproteinet, farmasøytiske og kosmetiske sammensetninger som inneholder transportproteinet, og deres anvendelse.
NO20071825A 2004-09-06 2007-04-10 Transportprotein som blir brukt til å innføre kjemiske forbindelser i nerveceller NO340732B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004043009A DE102004043009A1 (de) 2004-09-06 2004-09-06 Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
PCT/EP2005/009554 WO2006027207A1 (de) 2004-09-06 2005-09-06 Transportprotein zum einbringen chemischer verbindungen in nervenzellen

Publications (2)

Publication Number Publication Date
NO20071825L true NO20071825L (no) 2007-06-06
NO340732B1 NO340732B1 (no) 2017-06-06

Family

ID=35583367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071825A NO340732B1 (no) 2004-09-06 2007-04-10 Transportprotein som blir brukt til å innføre kjemiske forbindelser i nerveceller

Country Status (19)

Country Link
US (3) US8293230B2 (no)
EP (1) EP1786832B1 (no)
JP (2) JP5357425B2 (no)
KR (3) KR101277280B1 (no)
CN (1) CN101056888B (no)
AU (1) AU2005281830B2 (no)
BR (1) BRPI0514943A (no)
CA (1) CA2578097C (no)
DE (1) DE102004043009A1 (no)
DK (1) DK1786832T3 (no)
EA (1) EA014526B1 (no)
ES (1) ES2390279T3 (no)
IL (1) IL181481A (no)
IN (1) IN2014DN01950A (no)
MX (1) MX2007002737A (no)
NO (1) NO340732B1 (no)
UA (1) UA93359C2 (no)
WO (1) WO2006027207A1 (no)
ZA (1) ZA200701896B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267008B1 (en) 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1861419B1 (en) * 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
HRP20090382T1 (hr) 2005-06-17 2009-09-30 Merz Pharma Gmbh & Co.Kgaa Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom
DK1931379T3 (da) * 2005-10-07 2013-08-19 Sec Dep For Health Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme
WO2008008805A2 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
AU2007272515B2 (en) * 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
AU2007347781B2 (en) * 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
JP2008169166A (ja) * 2007-01-14 2008-07-24 Tokyo Univ Of Agriculture & Technology 糖結合性ポリペプチド、複合材料、及び薬剤送達システム
AU2008256418A1 (en) 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
CA2690773C (en) * 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
WO2009015840A2 (en) * 2007-07-27 2009-02-05 Merz Pharma Gmbh & Co. Kgaa Polypeptide for targeting of neural cells
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US20110190216A1 (en) * 2008-07-29 2011-08-04 Florida State University Research Foundation Materials and methods for treatment of spinal muscular atrophy and taxane-induced peripheral neuropathy (tipn)
ES2592314T3 (es) 2008-08-29 2016-11-29 Merz Pharma Gmbh & Co. Kgaa Neurotoxinas clostridiales con persistencia modificada
ES2426667T3 (es) 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
MX359480B (es) * 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
EP2897638A1 (en) 2012-09-24 2015-07-29 Montana State University-Bozeman Recombinant lactococcus lactis expressing escherichia coli colonization factor antigen i (cfa/i) fimbriae and their methods of use
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MX380066B (es) 2014-12-23 2025-03-11 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180021703A (ko) * 2015-05-15 2018-03-05 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 선택된 세포로 분자를 전달하도록 개조된 조작된 클로스트리디움 보툴리눔 독소
MX2018002183A (es) 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3362033B1 (en) * 2015-11-20 2023-01-04 Colgate-Palmolive Company Single phase whitening dentifrice with high purity metaphosphate abrasive
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
CN109790204A (zh) * 2016-09-29 2019-05-21 益普生生物制药有限公司 杂合神经毒素
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
TWI810228B (zh) 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 自主神經系統障礙之治療
WO2019243376A1 (en) 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
JP7604365B2 (ja) 2018-09-28 2024-12-23 イプセン バイオファーム リミテッド 細胞ベースのクロストリジウム神経毒アッセイ
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
MA66538B1 (fr) 2021-09-16 2026-03-31 Ipsen Biopharm Limited Bont/a modifiée destinée à être utilisée dans le traitement de la dystonie cervicale
CA3228712A1 (en) 2021-09-23 2023-03-30 Nicolae GRIGORE Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
AU2022392458A1 (en) 2021-11-22 2024-05-02 Ipsen Biopharm Limited Treatment of pain
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206361D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202206362D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
EP4593873A1 (en) 2022-09-30 2025-08-06 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025093845A1 (en) 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
GB9410871D0 (en) 1994-05-31 1994-07-20 Imperial College Modification of tetanus toxin for use as a transport protein
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6545126B1 (en) 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
US7235521B1 (en) 1999-05-17 2007-06-26 United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
EP2267008B1 (en) * 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7196189B2 (en) 2001-10-09 2007-03-27 Microbia, Inc. love variant regulator molecules
US20070118934A1 (en) 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
KR20030097047A (ko) * 2002-06-18 2003-12-31 신찬영 초음파기화식냉풍기
GB0216865D0 (en) * 2002-07-19 2002-08-28 Microbiological Res Authority Targetted agents for nerve regeneration
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US20050129677A1 (en) 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB2416692A (en) * 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
ES2526913T3 (es) * 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina 2 botulínica
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
JP4994241B2 (ja) 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) * 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US8445650B2 (en) 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain

Also Published As

Publication number Publication date
KR101277280B1 (ko) 2013-06-20
BRPI0514943A (pt) 2008-07-01
JP5833039B2 (ja) 2015-12-16
ES2390279T3 (es) 2012-11-08
UA93359C2 (ru) 2011-02-10
HK1100291A1 (en) 2007-09-14
CN101056888B (zh) 2012-07-04
KR20130043251A (ko) 2013-04-29
JP5357425B2 (ja) 2013-12-04
US20150030584A1 (en) 2015-01-29
CA2578097C (en) 2014-05-20
JP2008512089A (ja) 2008-04-24
US9422344B2 (en) 2016-08-23
MX2007002737A (es) 2008-03-05
US9234011B2 (en) 2016-01-12
NO340732B1 (no) 2017-06-06
US20070299008A1 (en) 2007-12-27
US8293230B2 (en) 2012-10-23
CA2578097A1 (en) 2006-03-16
KR20070059090A (ko) 2007-06-11
JP2013139454A (ja) 2013-07-18
AU2005281830A1 (en) 2006-03-16
WO2006027207A1 (de) 2006-03-16
EA200700408A1 (ru) 2007-08-31
KR101602128B1 (ko) 2016-03-10
ZA200701896B (en) 2009-05-27
DK1786832T3 (da) 2012-10-22
EP1786832A1 (de) 2007-05-23
EA014526B1 (ru) 2010-12-30
AU2005281830B2 (en) 2011-12-22
IL181481A (en) 2015-10-29
IL181481A0 (en) 2007-07-04
US20130116191A1 (en) 2013-05-09
EP1786832B1 (de) 2012-07-18
CN101056888A (zh) 2007-10-17
IN2014DN01950A (no) 2015-07-10
DE102004043009A1 (de) 2006-03-23
KR20140063901A (ko) 2014-05-27

Similar Documents

Publication Publication Date Title
MX2007002737A (es) Proteina transportadora para la introduccion de compuestos quimicos en celulas neuronales.
EA200702323A1 (ru) Носитель для доставки в нервные клетки
BRPI0610197B8 (pt) anticorpo de ligação à esclerostina, processo para a produção do mesmo, composição farmacêutica que compreende o dito anticorpo e vetor de clonagem ou expressão
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
WO2007016150A3 (en) Mutated pseudomonas exotoxins with reduced antigenicity
MY174493A (en) Binding agents
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BR112021024553A2 (pt) Molécula de ligação específica para cd73 e uso de molécula de ligação
MX346731B (es) Producción de proteínas heteromultiméricas.
NO20083268L (no) Antistoffer anvist til HER-3 og anvendelser derav
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA201270758A1 (ru) Мутанты fgf21 и их применение
DK1716178T3 (da) Mindre immunogene bindingsmolekyler
NZ602054A (en) Anti-nerve growth factor (ngf) antibody compositions
EP1871426A4 (en) SMALL, ACTIVATING RNA MOLECULES AND METHOD OF USE THEREOF
EA201690355A1 (ru) Инсектицидные полипептиды с широким спектром активности и их применения
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
ZA202210624B (en) Anti-cd137 construct and use thereof
WO2010033007A3 (ko) 특정 아미노산의 trna와의 동시 발현을 통한 특정 아미노산 함량이 높은 단백질의 제조방법
WO2024194686A3 (en) Anti-phosphocholine antibodies and methods of use thereof
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung
WO2007149570A3 (en) Modulation of protein levels in plants
WO2006116192A3 (en) Irta-1 antibodies and their uses
WO2007014076A3 (en) Methods of producing modified assembly lines and related compositions

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees